Expression Analysis of Imbalanced Genes in Prostate Carcinoma Using Tissue Microarrays

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Dec 6

PMID 17146477

Citations 31

Authors

I Prowatke

F Devens

A Benner

E F Grone

D Mertens

H-J Grone

P Lichter

S Joos

Affiliations

Soon will be listed here.

Abstract

To identify candidate genes relevant for prostate tumour prognosis and progression, we performed an exhaustive gene search in seven previously described genomic-profiling studies of 161 prostate tumours, and four expression profiling studies of 61 tumours. From the resulting list of candidate genes, six were selected for protein-expression analysis based on the availability of antibodies applicable to paraffinised tissue: fatty acid synthase (FASN), MYC, beta-adrenergic receptor kinase 1 (BARK1, GRK2) the catalytic subunits of protein phosphatases PP1alpha (PPP1CA) and PP2A (PPP2CB) and metastasis suppressor NM23-H1. These candidates were analysed by immunohistochemistry (IHC) on a tissue microarray containing 651 cores of primary prostate cancer samples and benign prostatic hyperplasias (BPH) from 175 patients. In univariate analysis, expression of PP1alpha (P=0.001) was found to strongly correlate with Gleason score. MYC immunostaining negatively correlated with both pT-stage and Gleason score (P<0.001 each) in univariate as well as in multivariate analysis. Furthermore, a subgroup of patients with high Gleason scores was characterised by a complete loss of BARK1 protein (P=0.023). In conclusion, our study revealed novel molecular markers of potential diagnostic and therapeutic relevance for prostate carcinoma.

Citing Articles

Exploring the potential biological function of GRK2 in colorectal cancer.

Gao M, Liang X, Fan M, Wu Y, Dong M, Du R Funct Integr Genomics. 2024; 24(2):51.

PMID: 38446273 DOI: 10.1007/s10142-024-01322-1.

A common molecular and cellular pathway in developing Alzheimer and cancer.

Ali M, Wani S, Dey T, Sridhar S, Qadrie Z Biochem Biophys Rep. 2024; 37:101625.

PMID: 38225990 PMC: 10788207. DOI: 10.1016/j.bbrep.2023.101625.

The grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography.

Nilsson E, Sandgren K, Grefve J, Jonsson J, Axelsson J, Keeratijarut Lindberg A Commun Med (Lond). 2023; 3(1):164.

PMID: 37945817 PMC: 10636013. DOI: 10.1038/s43856-023-00394-7.

The GRKs Reactome: Role in Cell Biology and Pathology.

Chaudhary P, Kim S Int J Mol Sci. 2021; 22(7).

PMID: 33806057 PMC: 8036551. DOI: 10.3390/ijms22073375.

Whole genome sequencing analysis of high confidence variants of B-cell lymphoma in Canis familiaris.

Sparks A, Woods J, Bienzle D, Wood G, Coomber B PLoS One. 2020; 15(8):e0238183.

PMID: 32857815 PMC: 7454977. DOI: 10.1371/journal.pone.0238183.

References

Wolter H, Trijic D, Gottfried H, Mattfeldt T . Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. Eur Urol. 2002; 41(3):328-34. DOI: 10.1016/s0302-2838(02)00035-0. View

Rhodes D, Barrette T, Rubin M, Ghosh D, Chinnaiyan A . Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002; 62(15):4427-33. View

Steeg P . Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003; 3(1):55-63. DOI: 10.1038/nrc967. View

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M . Cancer statistics, 2003. CA Cancer J Clin. 2003; 53(1):5-26. DOI: 10.3322/canjclin.53.1.5. View

Paris P, Albertson D, Alers J, Andaya A, Carroll P, Fridlyand J . High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol. 2003; 162(3):763-70. PMC: 1868117. DOI: 10.1016/S0002-9440(10)63873-4. View

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T . Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003; 1(10):707-15. View

Garcia A, Cayla X, Guergnon J, Dessauge F, Hospital V, Rebollo M . Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie. 2003; 85(8):721-6. DOI: 10.1016/j.biochi.2003.09.004. View

Baron A, Migita T, Tang D, Loda M . Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem. 2003; 91(1):47-53. DOI: 10.1002/jcb.10708. View

Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y . Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res. 1993; 84(10):1050-4. PMC: 5919063. DOI: 10.1111/j.1349-7006.1993.tb02800.x. View

10.

Igawa M, Rukstalis D, Tanabe T, Chodak G . High levels of nm23 expression are related to cell proliferation in human prostate cancer. Cancer Res. 1994; 54(5):1313-8. View

11.

Shurbaji M, Kalbfleisch J, Thurmond T . Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol. 1996; 27(9):917-21. DOI: 10.1016/s0046-8177(96)90218-x. View

12.

Jenkins R, Qian J, Lieber M, Bostwick D . Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997; 57(3):524-31. View

13.

Frydenberg M, Stricker P, Kaye K . Prostate cancer diagnosis and management. Lancet. 1997; 349(9066):1681-7. DOI: 10.1016/S0140-6736(96)07393-X. View

14.

Berndt N, Dohadwala M, Liu C . Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells. Curr Biol. 1997; 7(6):375-86. DOI: 10.1016/s0960-9822(06)00185-0. View

15.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

16.

Sattler H, Rohde V, Bonkhoff H, Zwergel T, Wullich B . Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate. 1999; 39(2):79-86. DOI: 10.1002/(sici)1097-0045(19990501)39:2<79::aid-pros1>3.0.co;2-2. View

17.

Sato K, Qian J, Slezak J, Lieber M, Bostwick D, Bergstralh E . Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst. 1999; 91(18):1574-80. DOI: 10.1093/jnci/91.18.1574. View

18.

Chan K, Guan X, Ng I . High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol. 2005; 35(11):1324-31. DOI: 10.1016/j.humpath.2004.06.012. View

19.

Kasbohm E, Guo R, Yowell C, Bagchi G, Kelly P, Arora P . Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem. 2005; 280(12):11583-9. DOI: 10.1074/jbc.M414423200. View

20.

Royuela M, De Miguel M, Ruiz A, Fraile B, Arenas M, Romo E . Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw. 2000; 11(1):119-27. View